メカセルミン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/05/28 18:04:18」(JST)
[Wiki en表示]
Mecasermin
|
| Clinical data |
| AHFS/Drugs.com |
monograph |
| Pregnancy cat. |
C (US) |
| Legal status |
℞-only (US) |
| Routes |
Subcutaneous |
| Identifiers |
| CAS number |
68562-41-4 N |
| ATC code |
H01AC03 |
| DrugBank |
DB01277 |
| UNII |
7GR9I2683O Y |
| KEGG |
D04870 N |
| ChEMBL |
CHEMBL1201716 N |
| Chemical data |
| Formula |
C331H512N94O101S7 |
| Mol. mass |
7648.67 g/mol |
N (what is this?) (verify)
|
Mecasermin (INN, brand name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]
This drug is not to be confused with mecasermin rinfabate (trade name: Iplex), which is the binary complex of recombinant human IGF-1 (rhIGF-1) and the binding protein that IGF-1 is naturally adhered to in the human body.
References [edit]
- ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management 5 (3): 553–9. PMC 2724186. PMID 19707272.
- ^ "Increlex". Drugs.com. Retrieved 10 January 2010.
|
Hypothalamic-pituitary hormones and analogues (H01)
|
|
| Hypothalamic |
|
GNRH
|
- Agonists: Gonadorelin
- Nafarelin
- Histrelin
Antagonists: Cetrorelix
- Ganirelix
|
|
|
Somatostatin
|
- Agonists: Lanreotide
- Octreotide
- Pasireotide
- Vapreotide
|
|
|
| Anterior pituitary |
|
ACTH
|
- Agonists: Corticotropin
- Cosyntropin
- Tetracosactide
|
|
|
GH
|
- Agonists: IGF-1 (Mecasermin/Mecasermin rinfabate)
- Sermorelin
- Somatrem
Antagonists: Pegvisomant
|
|
|
TSH
|
|
|
|
| Posterior pituitary |
|
Oxytocin
|
- Agonists: Carbetocin
- Demoxytocin
Antagonists: Atosiban
|
|
|
Vasopressin
|
- Agonists: Argipressin
- Desmopressin
- Felypressin
- Lypressin
- Ornipressin
- Terlipressin
Antagonists: Conivaptan
- Demeclocycline
- Lixivaptan
- Mozavaptan
- Nelivaptan
- Relcovaptan
- Satavaptan
- Tolvaptan
|
|
|
|
|
|
noco (d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Expression of Recombinant Human Insulin-like Growth Factor Type 1 (rhIGF-1) in Escherichia coli.
- Iranpoor H1, Omidinia E2, Vatankhah V3, Gharanjik V4, Shahbazi M5.
- Avicenna journal of medical biotechnology.Avicenna J Med Biotechnol.2015 Jul-Sep;7(3):101-5.
- BACKGROUND: Human insulin-like growth factor type 1 (hIGF-1) is a protein consisting of 70 amino acids (MW=7.6 kDa) and mainly synthesized by liver. Mecasermin (Trade name INCRELEX) is the synthetic form of the protein which is used as an effective treatment for particular disorders such as short st
- PMID 26306149
- Desensitization to mecasermin in an insulin-like growth factor 1-deficient patient.
- Gutiérrez-Fernández D1, Moreno-Ancillo Á2, Foncubierta-Fernández A3, López-Martínez I4, Lechuga-Sancho A4, Fernández-Anguita MJ5.
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.Ann Allergy Asthma Immunol.2015 Jun;114(6):523-5. doi: 10.1016/j.anai.2015.03.004. Epub 2015 Apr 3.
- PMID 25843163
- The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.
- Ren J1, Anversa P2.
- Biochemical pharmacology.Biochem Pharmacol.2015 Feb 15;93(4):409-17. doi: 10.1016/j.bcp.2014.12.006. Epub 2014 Dec 23.
- Metabolic syndrome is a cluster of risk factors including obesity, dyslipidemia, hypertension, and insulin resistance. A number of theories have been speculated for the pathogenesis of metabolic syndrome including impaired glucose and lipid metabolism, lipotoxicity, oxidative stress, interrupted neu
- PMID 25541285
Japanese Journal
- 545 組換えメカセルミン(IGF-I)の大量精製
- 544 大腸菌HB101によるメカセルミン(IGF-1)融合蛋白の高生産
- Large Scale Purification of Recombinant Insulin-Like Growth Factor I (IGF-I, Mecasermin) from a Fused Protein Produced in Escherichia coli
- Journal of fermentation and bioengineering 82(2), 134-139, 1996-08-25
- NAID 110002682339
Related Links
- Mecasermin is made by Tercica Pharmaceuticals (Increlex) as a treatment for 'short stature' due to severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies ...
- Mecasermin can cause side effects that may impair thinking, reactions, or physical abilities. The child should avoid driving or doing anything else that requires alertness or coordination for the first 2 or 3 hours after a mecasermin ...
★リンクテーブル★
[★]
- 英
- mecasermin
- 商
- ソマゾン
- 関
- ソマトメジンC